The University of Chicago Header Logo

Connection

Mark Talamonti to Leukopenia

Back to Details
This is a "connection" page, showing publications Mark Talamonti has written about Leukopenia.
Mark Talamonti
Connection Strength
0.095
Leukopenia
  1. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):476-82.
    View in: PubMed
    Score: 0.095
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.